Coverage
-
March 02, 2017
Concordia Pharmaceuticals Inc. on Thursday saw its $730,000 damages award against Method Pharmaceuticals LLC trebled to $2.2 million when a Virginia federal judge said an enhancement was warranted in the false advertising suit over Method's representation its irritable bowel syndrome medication was a valid generic substitute.
1 other articles on this case.
View all »